Cargando…
Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials
BACKGROUND: Pandemic events often trigger a surge of clinical trial activity aimed at rapidly evaluating therapeutic or preventative interventions. Ensuring rapid public access to the complete and unbiased trial record is particularly critical for pandemic research given the urgent associated public...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185489/ https://www.ncbi.nlm.nih.gov/pubmed/34103009 http://dx.doi.org/10.1186/s12874-021-01324-8 |
_version_ | 1783704798046978048 |
---|---|
author | Jones, Christopher W. Adams, Amanda C. Murphy, Elizabeth King, Rachel P. Saracco, Benjamin Stesis, Karen R. Cavanaugh, Susan Roberts, Brian W. Platts-Mills, Timothy F. |
author_facet | Jones, Christopher W. Adams, Amanda C. Murphy, Elizabeth King, Rachel P. Saracco, Benjamin Stesis, Karen R. Cavanaugh, Susan Roberts, Brian W. Platts-Mills, Timothy F. |
author_sort | Jones, Christopher W. |
collection | PubMed |
description | BACKGROUND: Pandemic events often trigger a surge of clinical trial activity aimed at rapidly evaluating therapeutic or preventative interventions. Ensuring rapid public access to the complete and unbiased trial record is particularly critical for pandemic research given the urgent associated public health needs. The World Health Organization (WHO) established standards requiring posting of results to a registry within 12 months of trial completion and publication in a peer reviewed journal within 24 months of completion, though compliance with these requirements among pandemic trials is unknown. METHODS: This cross-sectional analysis characterizes availability of results in trial registries and publications among registered trials performed during the 2009 H1N1 influenza, 2014 Ebola, and 2016 Zika pandemics. We searched trial registries to identify clinical trials testing interventions related to these pandemics, and determined the time elapsed between trial completion and availability of results in the registry. We also performed a comprehensive search of MEDLINE via PubMed, Google Scholar, and EMBASE to identify corresponding peer reviewed publications. The primary outcome was the compliance with either of the WHO’s established standards for sharing clinical trial results. Secondary outcomes included compliance with both standards, and assessing the time elapsed between trial completion and public availability of results. RESULTS: Three hundred thirty-three trials met eligibility criteria, including 261 H1N1 influenza trials, 60 Ebola trials, and 12 Zika trials. Of these, 139 (42%) either had results available in the trial registry within 12 months of study completion or had results available in a peer-reviewed publication within 24 months. Five trials (2%) met both standards. No results were available in either a registry or publication for 59 trials (18%). Among trials with registered results, a median of 42 months (IQR 16–76 months) elapsed between trial completion and results posting. For published trials, the median elapsed time between completion and publication was 21 months (IQR 9–34 months). Results were available within 24 months of study completion in either the trial registry or a peer reviewed publication for 166 trials (50%). CONCLUSIONS: Very few trials performed during prior pandemic events met established standards for the timely public dissemination of trial results. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01324-8. |
format | Online Article Text |
id | pubmed-8185489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81854892021-06-08 Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials Jones, Christopher W. Adams, Amanda C. Murphy, Elizabeth King, Rachel P. Saracco, Benjamin Stesis, Karen R. Cavanaugh, Susan Roberts, Brian W. Platts-Mills, Timothy F. BMC Med Res Methodol Research Article BACKGROUND: Pandemic events often trigger a surge of clinical trial activity aimed at rapidly evaluating therapeutic or preventative interventions. Ensuring rapid public access to the complete and unbiased trial record is particularly critical for pandemic research given the urgent associated public health needs. The World Health Organization (WHO) established standards requiring posting of results to a registry within 12 months of trial completion and publication in a peer reviewed journal within 24 months of completion, though compliance with these requirements among pandemic trials is unknown. METHODS: This cross-sectional analysis characterizes availability of results in trial registries and publications among registered trials performed during the 2009 H1N1 influenza, 2014 Ebola, and 2016 Zika pandemics. We searched trial registries to identify clinical trials testing interventions related to these pandemics, and determined the time elapsed between trial completion and availability of results in the registry. We also performed a comprehensive search of MEDLINE via PubMed, Google Scholar, and EMBASE to identify corresponding peer reviewed publications. The primary outcome was the compliance with either of the WHO’s established standards for sharing clinical trial results. Secondary outcomes included compliance with both standards, and assessing the time elapsed between trial completion and public availability of results. RESULTS: Three hundred thirty-three trials met eligibility criteria, including 261 H1N1 influenza trials, 60 Ebola trials, and 12 Zika trials. Of these, 139 (42%) either had results available in the trial registry within 12 months of study completion or had results available in a peer-reviewed publication within 24 months. Five trials (2%) met both standards. No results were available in either a registry or publication for 59 trials (18%). Among trials with registered results, a median of 42 months (IQR 16–76 months) elapsed between trial completion and results posting. For published trials, the median elapsed time between completion and publication was 21 months (IQR 9–34 months). Results were available within 24 months of study completion in either the trial registry or a peer reviewed publication for 166 trials (50%). CONCLUSIONS: Very few trials performed during prior pandemic events met established standards for the timely public dissemination of trial results. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01324-8. BioMed Central 2021-06-08 /pmc/articles/PMC8185489/ /pubmed/34103009 http://dx.doi.org/10.1186/s12874-021-01324-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Jones, Christopher W. Adams, Amanda C. Murphy, Elizabeth King, Rachel P. Saracco, Benjamin Stesis, Karen R. Cavanaugh, Susan Roberts, Brian W. Platts-Mills, Timothy F. Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials |
title | Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials |
title_full | Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials |
title_fullStr | Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials |
title_full_unstemmed | Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials |
title_short | Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials |
title_sort | delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 h1n1, 2014 ebola, and 2016 zika clinical trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185489/ https://www.ncbi.nlm.nih.gov/pubmed/34103009 http://dx.doi.org/10.1186/s12874-021-01324-8 |
work_keys_str_mv | AT joneschristopherw delaysinreportingandpublishingtrialresultsduringpandemicscrosssectionalanalysisof2009h1n12014ebolaand2016zikaclinicaltrials AT adamsamandac delaysinreportingandpublishingtrialresultsduringpandemicscrosssectionalanalysisof2009h1n12014ebolaand2016zikaclinicaltrials AT murphyelizabeth delaysinreportingandpublishingtrialresultsduringpandemicscrosssectionalanalysisof2009h1n12014ebolaand2016zikaclinicaltrials AT kingrachelp delaysinreportingandpublishingtrialresultsduringpandemicscrosssectionalanalysisof2009h1n12014ebolaand2016zikaclinicaltrials AT saraccobenjamin delaysinreportingandpublishingtrialresultsduringpandemicscrosssectionalanalysisof2009h1n12014ebolaand2016zikaclinicaltrials AT stesiskarenr delaysinreportingandpublishingtrialresultsduringpandemicscrosssectionalanalysisof2009h1n12014ebolaand2016zikaclinicaltrials AT cavanaughsusan delaysinreportingandpublishingtrialresultsduringpandemicscrosssectionalanalysisof2009h1n12014ebolaand2016zikaclinicaltrials AT robertsbrianw delaysinreportingandpublishingtrialresultsduringpandemicscrosssectionalanalysisof2009h1n12014ebolaand2016zikaclinicaltrials AT plattsmillstimothyf delaysinreportingandpublishingtrialresultsduringpandemicscrosssectionalanalysisof2009h1n12014ebolaand2016zikaclinicaltrials |